The coronavirus disease (COVID-19) is caused by a positive-stranded RNA virus called severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), belonging to the Coronaviridae family. This virus originated in Wuhan City, China, and became the cause of a multiwave pandemic that has killed 3.46 million people worldwide as of May 22, 2021. The havoc intensified with the emergence of SARS-CoV-2 variants (B.1.1.7; Alpha, B.1.351; Beta, P.1; Gamma, B.1.617; Delta, B.1.617.2; Delta-plus, B.1.525; Eta, and B.1.429; Epsilon etc.) due to mutations generated during replication. More variants may emerge to cause additional pandemic waves. The most promising approach for combating viruses and their emerging variants lies in prophylactic vaccines. Several vaccine candidates are being developed using various platforms, including nucleic acids, live attenuated virus, inactivated virus, viral vectors, and protein-based subunit vaccines. In this unprecedented time, 12 vaccines against SARS-CoV-2 have been phased in following WHO approval, 184 are in the preclinical stage, and 100 are in the clinical development process. Many of them are directed to elicit neutralizing antibodies against the viral spike protein (S) to inhibit viral entry through the ACE-2 receptor of host cells. Inactivated vaccines, to the contrary, provide a wide range of viral antigens for immune activation. Being an intracellular pathogen, the cytotoxic CD8 + T Cell (CTL) response remains crucial for all viruses, including SARS-CoV-2, and needs to be explored in detail. In this review, we try to describe and compare approved vaccines against SARS-CoV-2 that are currently being distributed either after phase III clinical trials or for emergency use. We discuss immune responses induced by various candidate vaccine formulations; their benefits, potential limitations, and effectiveness against variants; future challenges, such as antibody-dependent enhancement (ADE); and vaccine safety issues and their possible resolutions. Most of the current vaccines developed against SARS-CoV-2 are showing either promising or compromised efficacy against new variants. Multiple antigen-based vaccines (multivariant vaccines) should be developed on different platforms to tackle future variants. Alternatively, recombinant BCG, containing SARS-CoV-2 multiple antigens, as a live attenuated vaccine should be explored for long-term protection. Irrespective of their efficacy, all vaccines are efficient in providing protection from disease severity. We must insist on vaccine compliance for all age groups and work on vaccine hesitancy globally to achieve herd immunity and, eventually, to curb this pandemic.
【저자키워드】 COVID-19, Vaccine, immune response, mutations, Spike protein, SARS CoV-2 variant, multivariant vaccines, booster dose, 【초록키워드】 coronavirus disease, viruses, neutralizing antibody, SARS-CoV-2, Efficacy, coronavirus, clinical trial, pandemic, Mutation, Inactivated Vaccines, Immunity, Vaccines, Neutralizing antibodies, Antibody-dependent enhancement, B.1.351, disease severity, variant, SARS-CoV-2 variant, Delta, B.1.617.2, Prophylactic, severe acute respiratory syndrome Coronavirus, virus, CD8, viral entry, Vaccine hesitancy, variants, Spike protein, ACE-2 receptor, Replication, China, Severe acute respiratory syndrome, T cell, Viral, pathogen, SARS-CoV-2 variants, nucleic acids, B.1.1.7, immune activation, Epsilon, herd immunity, immune responses, B.1.617, Wuhan, BCG, Effectiveness, Compliance, Gamma, viral vectors, vaccine candidate, Alpha, B.1.429, Beta, WHO, RNA virus, platform, CTL, inactivated, Emergency use, Coronavirus-2, intracellular pathogen, Eta, subunit vaccines, Live attenuated vaccine, attenuated vaccine, host cells, Attenuated Virus, viral spike protein, Viral antigen, acute respiratory syndrome, viral antigens, acute respiratory syndrome coronavirus, city, all age groups, acute respiratory syndrome coronavirus-2, approval, clinical development, candidate vaccine, contrary, Coronaviridae family, Multiple, B.1.525, potential limitations, being, MOST, Phase III clinical trials, multiple antigens, approach, combating, caused, inhibit, approved, elicit, the Coronaviridae, all age group, 【제목키워드】 challenge, Resolution,